# Evaluation of Ablation Index and VISITAG™ (ABI-173)

> **NCT03062046** · NA · COMPLETED · sponsor: **Biosense Webster, Inc.** · enrollment: 340 (actual)

## Conditions studied

- Paroxysmal Atrial Fibrillation

## Interventions

- **DEVICE:** RF ablation

## Key facts

- **NCT ID:** NCT03062046
- **Lead sponsor:** Biosense Webster, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-27
- **Primary completion:** 2019-03-27
- **Final completion:** 2019-03-27
- **Target enrollment:** 340 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062046, "Evaluation of Ablation Index and VISITAG™ (ABI-173)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03062046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*